Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesis. We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6). Here we show, through a combination of mapping critical recombinants, identifying individuals with germline mutations and screening known and predicted transcripts, that this gene encodes fumarate hydratase, an enzyme of the tricarboxylic acid cycle. Leiomyomatosis-associated mutations are predicted to result in absent or truncated protein, or substitutions or deletions of highly conserved amino acids. Activity of fumarate hydratase is reduced in lymphoblastoid cells from individuals with leiomyomatosis. This enzyme acts as a tumor suppressor in familial leiomyomata, and its measured activity is very low or absent in tumors from individuals with leiomyomatosis. Mutations in FH also occur in the recessive condition fumarate hydratase deficiency, and some parents of people with this condition are susceptible to leiomyomata. Thus, heterozygous and homozygous or compound heterozygous mutants have very different clinical phenotypes. Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“germline mutations in FH cause hereditary leiomyomatosis and renal cell cancer (HLRCC) (7).”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [7]
In the citing paper
“Familial cancer syndromes caused by fumarate hydratase (FH) or succinate dehydrogenase (SDH) deletion suggest that these TCA enzymes can behave as classical tumor suppressors.”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Tomlinson et al., 2002
In the citing paper
“Similarly, germline mutations in the broadly expressed enzyme fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell carcinoma, a familial syndrome of uterine and cutaneous leiomyomas and kidney cancer, without susceptibility to more common tumors (11).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [11]
In the citing paper
“In 2001, mutation of fumarate hydratase leading to its inactivation was discovered in renal cell cancer129. Mutation of this enzyme leads to fumarate accumulation not only in skin cancer and uterine leiomyomas but also in breast, bladder, and Leydig cell tumors130.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [130]
In the citing paper
“Consistently, heterozygous germline mutations in genes encoding the TCA cycle enzymes involved in the breakdown of these metabolites—SDH and FH—have been shown to facilitate the pathogenesis of certain rare cancers (e.g., paragangliomas) and inherited cancer-predisposition syndromes (181, 182, 183).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [183]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Inherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669
Fumarase C, the stable fumarase of Escherichia coli, is controlled by the soxRS regulon.
Liochev, S. I., & Fridovich, I. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5892 · Cited by 239
The VHL tumour-suppressor gene paradigm
Kaelin, W. G., & Maher, E. R. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01558-3 · Cited by 213 · cited 1×
“, individuals with von Hippel–Lindau syndrome are predisposed to both phaeochromocytomas and renal carcinoma”
BackgroundKiuru, M., Launonen, V., Hietala, M., Aittomäki, K., Vierimaa, O., Salovaara, R., Arola, J., Pukkala, E., Sistonen, P., Herva, R., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61757-9 · Cited by 209
Bourgeron, T., Chretien, D., Poggi-Bach, J., Doonan, S., Rabier, D., Letouzé, P., Munnich, A., Rötig, A., Landrieu, P., & Rustin, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117261 · Cited by 160
Alam, N. A., Bevan, S., Churchman, M., Barclay, E., Barker, K., Jaeger, E. E. M., Nelson, H. M., Healy, E., Pembroke, A. C., Friedmann, P. S., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/320124 · Cited by 160
Familial predisposition to uterine leiomyomas
Vikhliaeva, E. M., Сагдуллаевна, Х. З., & Nd, F. (1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)02533-i · Cited by 152 · cited 1×
“gif" NDATA ITEM> ]> Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesi”
Background
Cited by
Items 701–800 of 1,000
Components of cancer metabolism and therapeutic interventions
Singleterry, J., Sreedhar, A., & Zhao, Y. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.05.010 · Cited by 30
“A heterozygous FH mutation is correlated with renal cell carcinoma (Tomlinson et al., 2002).”
Mitochondrial Deficiencies in the Predisposition to Paraganglioma
Lussey‐Lepoutre, C., Buffet, A., Gimenez‐Roqueplo, A., & Favier, J. (2017) · Metabolites · doi:10.3390/metabo7020017 · Cited by 31
“Germline mutations in this tumour suppressor gene were first described in the predisposition to HRLCC syndrome (hereditary leiomyomatosis and renal cell cancer) also known as Reed Syndrome [40].”
BackgroundLameirinhas, A., Miranda‐Gonçalves, V., Henrique, R., & Jerónimo, C. (2019) · Genes · doi:10.3390/genes10040264 · Cited by 32
“The familiar form arises from hereditary leiomyoma renal cell carcinoma (HLRCC) syndrome and it due to fumarate hydratase (FH) gene germline mutations [29].”
BackgroundMitochondrial Diseases ‐ An Expanding Spectrum of Disorders and Affected Genes
von Kleist-Retzow, J., Schauseil-Zipf, U., Michalk, D. V., & Kunz, W. S. (2003) · Experimental Physiology · doi:10.1113/eph8802509 · Cited by 32
“E xp er im en ta l P hy si ol og y : T ra n sl at io n a n d In te gr at io n fibroids, skin leiomyomata and papillary renal cell cancer (Tomlinson et al. 2002).”
Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma
Walter, B. A., Gil, S. M., Naizhen, X., Kruhlak, M. J., Linehan, W. M., Srinivasan, R., & Merino, M. J. (2020) · Journal of Cancer · doi:10.7150/jca.35738 · Cited by 27
Li, H., Yang, W., Tu, X., Yu, L., Huang, D., Cheng, Y., Chang, B., Tang, S., Ge, H., Bao, L., et al. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.05.016 · Cited by 27
Tumour and patient factors in renal cell carcinoma—towards personalized therapy
Haddad, A., & Margulis, V. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.71 · Cited by 28
Reed's Syndrome: A Case of Multiple Cutaneous and Uterine Leiomyomas.
Emer, J. J., Solomon, S. M., & Mercer, S. E. (2011) · Europe PMC (PubMed Central) · Cited by 27
Lin, A., Anderson, S. L., Minard, K. I., & McAlister-Henn, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.266890 · Cited by 30
Mitochondrial disorders in renal tumors
Hervouet, É., & Godinot, C. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.03.003 · Cited by 30
Bonné, A., Vreede, L., Kuiper, R. P., Bodmer, D., Jansen, C., Eleveld, M. J., van Erp, F., Arkesteijn, G. J. A., Hoogerbrugge, N., van Ravenswaaij‐Arts, C. M. A., et al. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.07.005 · Cited by 28
Clinical Aspects of Renal Cell Carcinoma
Kırkalı, Z., & Öbek, C. (2003) · EAU Update Series · doi:10.1016/s1570-9124(03)00056-4 · Cited by 27
Confounding by linkage disequilibrium
Aïssani, B. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.130 · Cited by 28
Targeting the Metabolic Paradigms in Cancer and Diabetes
Bosso, M., Haddad, D., Madhoun, A. S. A., & Al‐Mulla, F. (2024) · Biomedicines · doi:10.3390/biomedicines12010211 · Cited by 30
Fumarate Esters as Angiogenesis Inhibitors: Key to Action in Psoriasis?
Arbiser, J. L. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.45 · Cited by 27
Pathological and molecular biological aspects of the renal epithelial neoplasms, up‐to‐date
Nagashima, Y., Inayama, Y., Kato, Y., Sakai, N., Kanno, H., Aoki, I., & Yao, M. (2004) · Pathology International · doi:10.1111/j.1440-1827.2004.01648.x · Cited by 26
Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma
Rana, H. Q., Rainville, I. R., & Vaidya, A. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000059 · Cited by 26
Trans-ethnic variation in germline variants of patients with renal cell carcinoma
Alaiwi, S. A., Nassar, A. H., Adib, E., Groha, S., Akl, E. W., McGregor, B. A., Esplin, E. D., Yang, S., Hatchell, K. E., Fusaro, V. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108926 · Cited by 26
Aı̈ssani, B., Zhang, K., & Wiener, H. W. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00241 · Cited by 26
Increased HIF1α in SDH and FH deficient tumors does not cause microsatellite instability
Lehtonen, H. J., Mäkinen, M. J., Kiuru, M. H., Laiho, P., Herva, R., van Minderhout, I. J. H. M., Hogendoorn, P. C. W., Cornelisse, C. J., Devilee, P., Launonen, V., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22819 · Cited by 30
“Germline mutations in the gene encoding fumarate hydratase (FH, fumarase), predispose to hereditary leiomyomatosis and renal cell cancer (HLRCC) characterized by susceptibility to benign uterine (ULM) and cutaneous leiomyomas, renal cell cancer (RCC) and uterine leiomyosarcoma (ULMS).(1,2) FH operates in the TCAC in c…”
BackgroundA novel mutation of the fumarase gene in a family with autosomal recessive fumarase deficiency
Remes, A. M., Filppula, S. A., Rantala, H., Leisti, J., Ruokonen, A., Sharma, S., Juffer, A. H., & Hiltunen, J. K. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0563-y · Cited by 26
Cancer and the Kidney: The Growth of Onco-nephrology
Perazella, M. A., Berns, J. S., & Rosner, M. H. (2013) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.09.002 · Cited by 28
Targeting ferroptosis in cancer: from mechanistic insights to therapeutic approaches
Wang, J., Guo, D., Jiang, S., Wu, W., & Gao, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00416-5 · Cited by 28
“In addition, fumarase plays an important role in the tricarboxylic acid (TCA) cycle by converting fumarate to malate, and is a tumor suppressor in leiomyoma and papillary renal cell carcinoma [148].”
Zeng, T., Tang, Z., Liang, L., Suo, D., Li, L., Li, J., Yuan, Y., Guan, X., & Li, Y. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12826 · Cited by 28
Sánchez‐Heras, A. B., Castillejo, A., García-Díaz, J. D. D., Robledo, M., Teulé, À., Sánchez‐Martínez, R., Zúñiga, Á., Lastra, E., Durán, M., Llort, G., et al. (2020) · Cancers · doi:10.3390/cancers12113277 · Cited by 28
Rajaram, K., Tewari, S. G., Wallqvist, A., & Prigge, S. T. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101897 · Cited by 26
Mehine, M. M., Ahvenainen, T., Khamaiseh, S., Härkönen, J., Reinikka, S., Heikkinen, T., Äyräväinen, A., Pakarinen, P. I., Härkki, P., Pasanen, A. M., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00425-3 · Cited by 26
“Using FH-deficient tumors derived from HLRCC patients and sporadic leiomyomas with biallelic loss of FH, we recently showed that AKR1B10 immunohistochemistry can act as a biomarker on protein-level as well [17].”
BackgroundHereditary Renal Cancer Syndromes
Yanus, G. A., Kuligina, E. S., & Имянитов, Е. Н. (2024) · Medical Sciences · doi:10.3390/medsci12010012 · Cited by 30
“FHTPS/HLRCC is caused by heterozygous germline inactivating mutations in the fumarate hydratase ( FH ) gene [126].”
BackgroundKręgiel, D. (2012) · InTech eBooks · doi:10.5772/48413 · Cited by 25
Intersections between mitochondrial sirtuin signaling and tumor cell metabolism
Herrera, K. N. G., Lee, J. J., & Haigis, M. C. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1031879 · Cited by 28
“In addition, under normoxic conditions, mutations in other tumor suppressors, such as succinate dehydrogenase or fumarate hydratase also stabilize HIF1 potentially via increased a-ketoglutarate levels (Baysal et al., 2004; Tomlinson et al., 2002).”
Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov, F. N. (2007) · PubMed · Cited by 25
Clonally related uterine leiomyomas are common and display branched tumor evolution
Mehine, M. M., Heinonen, H.-R., Sarvilinna, N. S., Pitkänen, E., Mäkinen, N., Katainen, R., Tuupanen, S., Bützow, R. C., Sjöberg, J., & Aaltonen, L. A. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv177 · Cited by 26
“Germlinemutations in FH, which encodes the citric acid cycle enzyme fumarase, predispose to the Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC, OMIM #150800) syndrome (9).”
BackgroundGenetic Kidney Cancer Syndromes
Ho, T. H., & Jonasch, E. W. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0129 · Cited by 25
SDH-deficient renal cell carcinoma – clinical, pathologic and genetic correlates: a case report
Kumar, R., Bonert, M., Naqvi, A. H., Zbuk, K. M., & Kapoor, A. (2018) · BMC Urology · doi:10.1186/s12894-018-0422-8 · Cited by 25
Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma
Karivedu, V., Jain, A., Eluvathingal, T. J., & Sidana, A. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0932-2 · Cited by 25
Czene, K., & Hemminki, K. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000052373.36963.12 · Cited by 25
Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma
Alkaissi, H. R., Taïeb, D., Lin, F. I., Rivero, J. D., Wang, K., Clifton-Bligh, R. J., & Pacák, K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf259 · Cited by 27
Xu, Y., Taylor, P. P., Andrade, J., Ueberheide, B. M., Shuch, B. M., Glazer, P. M., Bindra, R. S., Moran, M. F., Linehan, W. M., & Neel, B. G. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0901 · Cited by 29
“FH encodes a TCA cycle enzyme (8), whose loss-of-function results in Xu et al.”
BackgroundKuroda, N., Tsutsui, M., Iguchi, M., Nobuoka, E., Uehara, T., Sonobe, Y., Morinaga, Y., Shibuya, S., Oda, W., Yanai, H., et al. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151599 · Cited by 24
Uimari, O., Ahtikoski, A. M., Kämpjärvi, K., Bützow, R. C., Järvelä, I. Y., Ryynänen, M., Aaltonen, L. A., Vahteristo, P., & Kuismin, O. (2021) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14248 · Cited by 26
“HLRCC- related uterine leiomyomas have distinct tumor morphology based on (1) increased cellularity, (2) nuclear atypia/multinucleate cells, and (3) prominent eosinophilic nucleoli with a perinuclear halo, (4) eosinophilic cytoplasmic globules, (5) alveolar edema/hydropic degeneration, and (6) staghorn- like vessels.”
BackgroundHeterogeneity of the cancer cell line metabolic landscape
Shorthouse, D., Bradley, J., Critchlow, S. E., Bendtsen, C., & Hall, B. A. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211006 · Cited by 27
“…or alteration of a metabolic enzyme such as succinate dehydrogenase (SDH; Bardella et al , 2011; Thompson, 2009), fumarate hydratase (FH; Tomlinson et al , 2002) or isocitrate dehydrogenase (IDH; Waitkus et al , 2018), and there is an emerging and growing understanding of the impact of…”
BackgroundChapel, D. B., Sharma, A., Macciò, L., Bragantini, E., Zannoni, G. F., Yuan, L., Quade, B. J., Parra‐Herran, C., & Nucci, M. R. (2022) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000918 · Cited by 24
The prowess of metabolomics in cancer research: current trends, challenges and future perspectives
Taunk, K., Jajula, S., Bhavsar, P. P., Choudhari, M., Bhanuse, S. G., Tamhankar, A. S., Naiya, T., Kalita, B., & Rapole, S. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05041-w · Cited by 25
“Similarly the accumulation of succinate and fumarate results from mutations in succinate dehydrogenase and fumarase hydratase enzymes, respectively [40, 41].”
Mitochondria As A Target For Early Detection and Diagnosis of Cancer
Kagan, J., & Srivastava, S. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295477 · Cited by 26
Impact of Genetics on the Diagnosis and Treatment of Renal Cancer
Singer, E. A., Bratslavsky, G., Middelton, L. A., Srinivasan, R., & Linehan, W. M. (2010) · Current Urology Reports · doi:10.1007/s11934-010-0156-y · Cited by 24
“FH functions as a tumor suppressor, with both copies inactivated in tumors [41].”
Functional analysis of sucrase–isomaltase mutations from chronic lymphocytic leukemia patients
Rodríguez, D., Ramsay, A. J., Quesada, V., Garabaya, C., Campo, E., Freije, J. M. P., & López-Otín, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt078 · Cited by 25
“In addition, some metabolic enzymes have been recently found to act as tumor suppressors, such as the succinate dehydrogenase complex (26,27) and the tricarboxylic acid specific enzyme fumarate hydratase (28,29), or as oncogenes such as the isocitrate dehydrogenases (30).”
BackgroundHasumi, H., & Yao, M. (2018) · Cancer Science · doi:10.1111/cas.13503 · Cited by 24
“Upper panel shows low magnification and lower panel shows high magnification of H&E staining high frequency as well as type 2 papillary RCC in 10%-16% of the affected patients, which presents a very aggressive behavior and metastasizes even from a small-sized tumor, leading to very poor prognosis.29 In 2002, FH was id…”
BackgroundCurrent management of renal cell carcinoma and targeted therapy.
Canda, A. E., & Kırkalı, Z. (2006) · Urology journal./Urology jornal. · Cited by 24
Xie, J., Techritz, S., Haebel, S., Horn, A., Neitzel, H., Klose, J., & Schuelke, M. (2005) · PROTEOMICS · doi:10.1002/pmic.200401191 · Cited by 25
Molecular Markers for Early Detection of Renal Carcinoma
Skates, S. J., & Iliopoulos, O. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050010 · Cited by 28
Fumarate integrates metabolism and immunity in diseases
Cheng, J., Xiao, Y., & Jiang, P. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.008 · Cited by 25
Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer
Godel, M., Ortone, G., Anobile, D. P., Pasino, M., Randazzo, G., Riganti, C., & Kopecka, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050762 · Cited by 24
Genetics of enzymatic dysfunctions in metabolic disorders and cancer
Mahé, M., Rios-Fuller, T. J., Karolin, A., & Schneider, R. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1230934 · Cited by 26
Genetic Mechanisms Driving Uterine Leiomyoma Pathobiology, Epidemiology, and Treatment
Ramaiyer, M. S., El-Fattah, E. E. A., Kurt, I., & Borahay, M. A. (2024) · Genes · doi:10.3390/genes15050558 · Cited by 23
“…fumarate hydratase ( FH ) mutations have been demonstrated to be associated with an autosomal dominant disease named multiple cutaneous and uterine leiomyomatosis (MCUL) [54], as well as a rare disorder known as hereditary leiomyomatosis and renal cell carcinoma (HLRCC) [55,56]. the FH gene [56].”
BackgroundFumaric aciduria: Mild phenotype in a 8‐year‐old girl with novel mutations
Maradin, M., Fumić, K., Hansíková, H., Tesařová, M., Wenchich, L., Dorner, S., Sarnavka, V., Zeman, J., & Barić, I. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0321-0 · Cited by 23
The role of mutation of metabolism-related genes in genomic hypermethylation
Waterfall, J. J., Killian, J. K., & Meltzer, P. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.003 · Cited by 24
Multiple Hits for the Association of Uterine Fibroids on Human Chromosome 1q43
Aïssani, B., Wiener, H. W., & Zhang, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058399 · Cited by 27
“Collectively, the above reports and the following observations suggested a more complex genetic architecture for UL and highlighted the need for an intensive investigation of the chromosomal region spanning FH and flanking gene loci: i) absence of genotype-phenotype correlations [20,21], ii) marked genetic heterogenei…”
BackgroundResultInfluentialGenetics, Epigenetics and Cancer
Fymat, A. L. (2017) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2017.04.555634 · Cited by 23
“Gene expression in the prostate can be modulated by nutrition and lifestyle changes [17,18].”
BackgroundRodent models of pheochromocytoma, parallels in rodent and human tumorigenesis
Lussey‐Lepoutre, C., Buffet, A., Morin, A., Goncalves, J., & Favier, J. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2797-y · Cited by 25
Role of DNA damage and repair mechanisms in uterine fibroid/leiomyomas: a review
Toprani, S. M., & Mane, V. K. (2020) · Biology of Reproduction · doi:10.1093/biolre/ioaa157 · Cited by 25
Mitochondrial DNA Haplotypes as Genetic Modifiers of Cancer
Tasdogan, A., McFadden, D. G., & Mishra, P. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.004 · Cited by 25
Expanding the concepts and tools of metabolic engineering to elucidate cancer metabolism
Keibler, M. A., Fendt, S., & Stephanopoulos, G. N. (2012) · Biotechnology Progress · doi:10.1002/btpr.1629 · Cited by 27
Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC)
Wong, W., Tan, C. S., Lee, S. C., Yong, Y., Ooi, A. S., Ngeow, J. Y. Y., & Tan, M. H. (2014) · Familial Cancer · doi:10.1007/s10689-014-9703-x · Cited by 23
“Hereditary leiomyomatosis and renal cell cancer (HLRCC), also known as Reed syndrome, is characterised by variable development of multiple cutaneous leiomyomas, symptomatic uterine leiomyomas (uterine fibroids) and aggressive type II papillary renal cell carcinoma [1].”
BackgroundGenodermatoses with Cutaneous Tumors and Internal Malignancies
Somoano, B., & Tsao, H. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.08.011 · Cited by 24
Epigenetic Regulators of DNA Cytosine Modification: Promising Targets for Cancer Therapy
Jung, I., An, J., & Ko, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030654 · Cited by 24
Basic Mechanisms of Immunometabolites in Shaping the Immune Response
Ryan, D. G., Peace, C. G., & Hooftman, A. (2023) · Journal of Innate Immunity · doi:10.1159/000535452 · Cited by 25
“” Hereditary inactivating mutations in FH and resultant accumulation of fumarate are implicated in the onset of certain smooth muscle tumours and a highly aggressive form of kidney cancer, collectively termed hereditary leiomyomatosis and renal cell cancer (HLRCC) [114].”
BackgroundVoies moléculaires dans le cancer du rein : de la biologie aux traitements de demain
Edeline, J., Vigneau, C. M., Patard, J., & Rioux-Leclercq, N. C. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1066 · Cited by 22
“[13].”
The Role of Inflammation in Sarcoma
Radons, J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_11 · Cited by 23
Leiomiomatosis cutánea y uterina múltiple o síndrome de Reed: estudio retrospectivo de 13 casos
Collgros, H., Iglesias‐Sancho, M., Tribó-Boixareu, M. J., Creus-Vila, L., Umbert-Millet, P., & Salleras‐Redonnet, M. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2014.08.005 · Cited by 22
Boettcher, M., Lawson, A. R. J., Ladenburger, V., Fredebohm, J., Wolf, J. M., Hoheisel, J. D., Frezza, C., & Shlomi, T. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-158 · Cited by 22
“Loss-of-function mutations in FH have been associated with a number of diseases including hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a cancer syndrome characterized by a malignant form of renal cancer [12].”
BackgroundMitochondrial metabolic remodeling in response to genetic and environmental perturbations
Hollinshead, K. E. R., & Tennant, D. A. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1334 · Cited by 24
“FH, encoding the proximal downstream enzyme to SDH, is another mitochondrial tumor suppressor gene, the loss of which leads to hereditary leiomyomatosis and renal-cell cancer (HLRCC).(46) FHdeficient leiomyomas (a benign neoplasm) are highly penetrant, while RCC occurs slightly less FIGURE 2 | Succinate dehydrogenase…”
BackgroundEpigenomic tensor predicts disease subtypes and reveals constrained tumor evolution
Leistico, J. R., Saini, P., Futtner, C. R., Hejna, M., Omura, Y., Soni, P. N., Sandlesh, P., Milad, M. P., Wei, J., Bulun, S. E., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108927 · Cited by 25
Mitochondrial dysfunction and risk of cancer
Lund, M., Melbye, M., Díaz, L. J., Dunø, M., Wohlfahrt, J., & Vissing, J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.66 · Cited by 22
“…distinct cancer susceptibility syndrome, Hereditary Leiomyomatosis and Renal Cell Cancer (OMIM: 150800) (Kiuru et al, 2001; Launonen et al, 2001; Tomlinson et al, 2002), and mutations in the succinate dehydrogenase gene to predispose to various presentations of hereditary paragangliomas (Baysal…”
New Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes
Gimenez‐Roqueplo, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.012 · Cited by 25
Lacombe, V., Lenaers, G., & Urbanski, G. (2022) · Nutrients · doi:10.3390/nu14102058 · Cited by 23
Targeting Mitochondrial Metabolism to Reverse Radioresistance: An Alternative to Glucose Metabolism
Bian, C., Zheng, Z., Su, J., Wang, H., Chang, S., Xin, Y., & Jiang, X. M. (2022) · Antioxidants · doi:10.3390/antiox11112202 · Cited by 22
“Patients with hereditary leiomyomatosis, renal cell cancer (HLRCC), and a substantial accumulation of fumarate are susceptible to kidney cancer with type 2 papillary morphology, which is refractory to current radiotherapy [120,121].”
BackgroundVälimäki, N., Jokinen, V., Cajuso, T., Kuisma, H., Taira, A., Dagnaud, O., Ilves, S., Tolvanen, J., Pasanen, A. M., Palin, K., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.01.009 · Cited by 23
Genetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer
Piruat, J. I., & Millán‐Uclés, Á. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00200 · Cited by 23
“As for SDHD related tumors, tumor formation in FH heterozygotes is associated with loss of the second allele (52).”
BackgroundEmerging Entities in Renal Neoplasia
Mehra, R., Smith, S. C., Divatia, M. K., & Amin, M. B. (2015) · Surgical pathology clinics · doi:10.1016/j.path.2015.08.004 · Cited by 21
Heritable Cancer Syndromes Related to the Hypoxia Pathway
Henegan, J. C., & Gómez, C. R. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00068 · Cited by 22
“Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal-dominant hereditary cancer syndrome first associated with mutations in FH in 2002 (41).”
BackgroundLlamas‐Velasco, M., Requena, L., Adam, J., Frizzell, N., Hartmann, A., & Mentzel, T. (2016) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000580 · Cited by 22
“”(5) Therefore, pharmacological downregulation of HIF pathways that promote HIF hydroxylation might be a useful treatment for these patients.(6) However, there is no yet unquestionable proof that HIF1alpha activation in cells lacking FH is either necessary or sufficient for tumor formation.”
BackgroundWu, J., Zhang, P., Zhang, G., Wang, H., Gu, W., Dai, B., Zhang, H., Shi, G., Shen, Y., Zhu, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17894 · Cited by 21
“For example, ccRCC is characterized by silencing of the VHL gene and alteration of the hypoxia-inducible factor pathway [15–17]; mutations of the MET and FH genes are commonly observed in type I and type II PCC, respectively [18, 19]; and abnormal TP53 and BHD genes have been implicated in Chromophobe [20].”
BackgroundFive decades of urologic pathology: the accelerating expansion of knowledge in renal cell neoplasia
MacLennan, G. T., & Liang Cheng, C. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.09.009 · Cited by 21
Wise, L. A., & Laughlin-Tommaso, S. K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384978-6.00019-4 · Cited by 32
Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome
Raymond, V. M., Herron, C. M., Giordano, T. J., & Gruber, S. B. (2011) · Familial Cancer · doi:10.1007/s10689-011-9485-3 · Cited by 21
Therapies in inborn errors of oxidative metabolism
Schiff, M., Bénit, P., Jacobs, H. T., Vockley, J., & Rustin, P. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.04.006 · Cited by 23
“This triggers angiogenesis and might contribute to tumor development (paraganglioma for SDH deficiency [44], uterine and skin leiomyomata and papillary renal cell cancer for fumarase deficiency [46], even if a causal role for HIF in tumor development is debatable).”
BackgroundOwens, K. M., Modica-Napolitano, J. S., & Singh, K. K. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_1 · Cited by 24
Genetics of primary macronodular adrenal hyperplasia
Fragoso, M. C. B. V., Cavalcante, I. P., Ferreira, A. M., Mariani, B. M. P., & Lotfi, C. F. P. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.07.002 · Cited by 23
Tomar, M. S., Kumar, A., & Shrivastava, A. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149382 · Cited by 22
Fumarate hydratase as a therapeutic target in renal cancer
Kancherla, P., Daneshvar, M., Sager, R., Mollapour, M., & Bratslavsky, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1804862 · Cited by 20
Malouf, G. G., Joseph, R. W., Shah, A. Y., & Tannir, N. M. (2017) · PubMed · Cited by 20
Genetic disorders and renal cell carcinoma
Maranchie, J. K., & Linehan, W. M. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(02)00120-9 · Cited by 20
Multicentric papillary renal cell carcinoma associated with renal adenomatosis
Kiyoshima, K., Oda, Y., Nakamura, T., Migita, T., Okumura, K., Naito, S., & Tsuneyoshi, M. (2004) · Pathology International · doi:10.1111/j.1440-1827.2004.01618.x · Cited by 20
Genetic basis of kidney cancer: a model for developing molecular‐targeted therapies
Vira, M. A., Novakovic, K. R., Pinto, P. A., & Linehan, W. M. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06814.x · Cited by 20
A cancer‐predisposing “hot spot” mutation of the fumarase gene creates a dominant negative protein
Lorenzato, A., Olivero, M., Perro, M., Brière, J.-J., Rustin, P., & Renzo, M. F. D. (2007) · International Journal of Cancer · doi:10.1002/ijc.23209 · Cited by 20
“The R190H and the E319Q sequence variants had been previously identified as disease-causing mutations in FHD and HLRCC patients.(6,11) The E319Q mutation was selected as a positive control also because it had been studied thoroughly in previous works and characterized as far as kinetics and crystallography using the E.”
BackgroundCellular Respiration and Carcinogenesis
Sarangarajan, R., & Apte, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-435-3 · Cited by 23
Genetic Basis of Bilateral Renal Cancer: Implications for Evaluation and Management
Linehan, W. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0045 · Cited by 20
“HLRCC is characterized by germline mutation of the Krebs cycle enzyme, fumarate hydratase.(26,27) HLRCC-associated renal tumors are different from VHL, HPRC, or BHD kidney tumors.”
BackgroundKerimoglu, B., Lamb, C., McPherson, R. D., Ergen, E., Stone, E. M., & Ooi, A. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0661 · Cited by 19
The Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 27
Gene variants polymorphisms and uterine leiomyoma: an updated review
Upadhyay, S., & Dubey, P. K. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1330807 · Cited by 20
Metadata
- Authors
- The Multiple Leiomyoma Consortium
- Venue
- Nature Genetics
- Published
- 2002-02-25
- Volume
- 30
- Issue
- 4
- Pages
- 406-410
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1967291345
- Cited by
- 1,635
- References
- 17
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 64 · 2023: 57 · 2022: 65 · 2021: 80 · 2020: 93 · 2019: 86 · 2018: 81 · 2017: 90 · 2016: 106 · 2015: 89 · 2014: 85 · 2013: 82 · 2012: 82
- FWCI
- 56.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- U.S. Public Health Service (U59309)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- fumarate hydratase, FH gene, germline mutations, uterine fibroids, cutaneous leiomyoma, papillary renal cell carcinoma, cancer susceptibility, tumor suppressor, fumarate hydratase deficiency, compound heterozygosity, TCA cycle, fibroid pathogenesis
- MeSH terms
- Alleles, Carcinoma, Papillary, Carcinoma, Renal Cell, Chromosomes, Human, Pair 1, Exons, Female, Fumarate Hydratase, Genes, Dominant, Genetic Markers, Humans, Kidney Neoplasms, Leiomyoma, Male, Mutation, Pedigree, Recombination, Genetic, Uterine Neoplasms, Gene Deletion, In Situ Hybridization, Fluorescence, Sequence Analysis, DNA, Germ-Line Mutation, Leiomyoma, Epithelioid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.